It would seem that there were a number of stocks which declined sharply last week and the Immutep Limited (NASDAQ:IMMP) stock is one of those. Last Friday, the stock suffered from a selloff and went down by 2%.
Trading Data
On Friday, IMMP stock fell 2% at $3.81 with more than 203k shares, compared to its average volume of 375k shares. The stock has moved within a range of $3.7601 – 3.9400 after opening trade at $3.87.
Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha
The decline on Friday took the cumulative decline recorded by the Immutep stock for the previous week to as much as 11%. The biotech company was actually in considerable focus on Friday after it announced that it had been successful in enrolling the final patient in its expansion stage the Part A portion of the Phase II TACTI-OO2 study.
More importantly, the company also noted that the enrolment of patients for this particular study was completed across all the cohorts. It was also revealed that the total number of patients who are going to be part of the A, B and C portions of the trial now stands at 188.
In this context, it is perhaps also necessary to point out that the future interim data from the C portion of the trial had been presented by Immutep at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 that had been held from November 10 to November 14 this year.
Key Quote
Immutep CEO, Marc Voigt commented: “The completion of recruitment for our Phase II TACTI-002 trial marks the achievement of a major milestone for Immutep. Our clinical team and partners have worked hard to continue the pace of patient enrolment and finished recruitment much earlier than originally anticipated, despite some challenging conditions brought on by the COVID-19 pandemic. We are excited to be reporting further results from this trial in the coming months. We sincerely thank the patients and their families, and our various partners, for their ongoing support of this important trial.”
Technical Data
IMMP stock is below the 20-Day and 50-Day Moving averages of $4.16 and $4.08 respectively. However, the stock is above the 200-Day moving average of $3.74. The stock is down 12% in the past 3-month.
